Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

  • Naidoo J
  • Page D
  • Li B
 et al. 
  • 261

    Readers

    Mendeley users who have this article in their library.
  • 208

    Citations

    Citations of this article.

Abstract

Immune checkpoint antibodies that augment the PD-1/PD-L1 pathway have demonstrated anti-tumor activity across multiple malignancies, and gained recent regulatory approval as single agent therapy for the treatment of metastatic malignant melanoma and non-small cell lung cancer. Knowledge of toxicities associated with PD-1/PD-L1 blockade, as well as effective management algorithms for these toxicities, is pivotal in order to optimize clinical efficacy and safety. Herein, we review selected published and presented clinical studies investigating single agent anti-PD-1/PD-L1 therapy and trials of combination approaches with other standard anti-cancer therapies, in multiple tumor types. We summarize the key adverse events reported in these studies, and their management algorithms.

Author-supplied keywords

  • Adverse event
  • Anti-PD-1
  • Anti-PD-L1
  • Immune checkpoint antibody
  • Toxicity

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text

Authors

  • Mario LacoutureMemorial Sloan-Kettering Cancer Center

    Follow
  • J. Naidoo

  • D. B. Page

  • B. T. Li

  • L. C. Connell

  • K. Schindler

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free